Zeiss CIRRUS PathFinder: The AI Layer That Makes Your OCT Work Harder

At 100% Optical 2026, Zeiss showcased CIRRUS PathFinder — a fully integrated, deep learning AI support tool that works within the CIRRUS OCT platform to assist with macular scan interpretation. It is not an OCT in its own right. It is the intelligence layer that sits on top of one, designed to complement clinical workflow rather than replace it.

PathFinder automatically identifies macular OCT scans that may need closer review, colour-coding them to flag potential pathology. Reported specificity and sensitivity stand at 90%. For a busy independent practice running multiple OCT scans per session, that is a clinically meaningful tool — not because it replaces clinical judgement, but because it supports faster, more confident triage of a high-volume imaging workload.

Why This Is Relevant to Independent Practice

Independent practices are the primary source of hospital referrals in UK eye care. Over 700,000 patients are currently waiting to begin ophthalmology treatment across the UK. Unnecessary urgent referrals — particularly for suspected neovascular AMD — have been a documented problem in community optometry for years. AI-assisted OCT analysis addresses this directly: it helps practices refer the right patients at the right time, and justify those decisions clearly in the patient record.

For an independent practice with an OCT that charges for enhanced eye examinations, PathFinder also strengthens the clinical narrative around that premium. Patients paying for an enhanced exam deserve to know that the analysis of their scan carries an additional quality check. That is a story worth telling in the consultation room.

The Broader Picture

PathFinder is one of several AI interpretation tools now available to practices already running OCT. Topcon's IMAGEnet7 platform takes a similar approach — AI embedded into the clinical workflow rather than requiring separate upload or third-party analysis steps. The direction of travel across all the major manufacturers is the same: reduce the friction between imaging and decision-making, and keep the clinician in control of the interpretation.

For independent practice owners already running a CIRRUS OCT, PathFinder is worth a serious conversation with Zeiss. For those considering OCT investment or upgrade in 2026, the question is no longer just which hardware to buy — it is what AI capability comes with it, and how seamlessly it integrates into the workflow you already have.

Thinking about how diagnostic equipment investment fits into the wider financial picture of your independent practice? Grow Independent is the place to start that conversation.